Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis

被引:16
|
作者
Ishii, T
Sasaki, G
Hasegawa, T
Sato, S
Matsuo, N
Ogata, T
机构
[1] Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo 1548567, Japan
[2] Keio Univ, Sch Med, Dept Pediat, Tokyo 108, Japan
来源
JOURNAL OF UROLOGY | 2004年 / 172卷 / 01期
关键词
penis/abnormalities; testosterone; 5-alpha-reductase; polymorphism (genetics);
D O I
10.1097/01.ju.0000129005.84831.1e
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We report penile length (PL) responses to testosterone enanthate (TE) therapy for micropenis, and the relevance of the V89L polymorphism of SRD5A2 encoding the 5alpha-reductase type 2 and CAG repeat length polymorphism of AR encoding the androgen receptor. Materials and Methods: A total of 53 Japanese boys with micropenis (less than -2.0 SD) 0 to 13 years old who had no SRD5A2 or AR mutation were examined. TE was given at a dosage of 25 mg intramuscularly, and PL was measured at least 4 weeks after the injection. The 2 polymorphisms were determined by direct sequencing. Results: PLs became -2.0 SD or greater in all the boys after TE therapy (1 injection in 4 boys, 2 in 28, 3 in 19 and 4 in 2), with a significant increase in the medians of PLs (from 2.5 to 3.5 cm, p <0.0001) and SD score, (from -2.6 to -0.7, p <0.0001). The increment in actual PL at the first injection ranged from 0.2 to 1.5 cm (median 0.6) and was independent of age (r = 0.22, p = 0.12) and body surface area (r = 0.11, p =0.43), while that in PL SD score at the first injection ranged from 0.3 to 2.5 (1.0) and was inversely correlated with age (r = -0.33, p = 0.02) and body surface area (r = -0.37, p = 0.008). The actual PL increment at the first injection was also unrelated to initial PL (r = -0.03, p = 0.81). The median of actual PL increments at the first injection was similar among boys with V/V, V/L and L/L genotypes of SRD5A2 (0.6 cm in 18, 0.7 cm in 30 and 0.5 cm in 5, respectively, p = 0.77), and between boys with and without long CAG repeats (26 or greater) of AR (0.65 cm in 6 and 0.6 cm in 47, respectively, p = 0.77). In addition, there was no significant correlation between actual PL increment at the first injection and CAG repeat length (r = 0.06, p = 0.67). Conclusions: Our results suggest that administration of 25 mg TE is effective for micropenis in prepubertal boys with no SRD5A2 or AR mutation, with variable but significant PL increments, and that the penile responsiveness to TE therapy is independent of the V89L and the CAG repeat length polymorphisms.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 50 条
  • [31] SRD5A2 polymorphisms and measures of benign prostatic hyperplasia in a community-based cohort.
    Roberts, RO
    Bergstralh, EJ
    Farmer, SA
    Jacobson, DJ
    McGree, ME
    Cunningham, JM
    Hebbring, SJ
    Anderson, SA
    Thibodeau, SN
    Lieber, MM
    Jacobsen, SJ
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (11) : S2 - S2
  • [32] Identification of missense mutations in the SRD5A2 gene from patients with steroid 5α-reductase 2 deficiency
    Vilchis, F
    Méndez, JP
    Canto, P
    Lieberman, E
    Chávez, B
    CLINICAL ENDOCRINOLOGY, 2000, 52 (03) : 383 - 387
  • [33] The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism
    M Shiota
    N Fujimoto
    A Yokomizo
    A Takeuchi
    E Kashiwagi
    T Dejima
    K Kiyoshima
    J Inokuchi
    K Tatsugami
    M Eto
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 191 - 196
  • [34] Regulation of 5alpha-reductase type II (SRD5A2) gene expression by phytoestrogens
    Solipuram, Rajasree
    Naragoni, Srivatcha
    Gray, Wesley G.
    CANCER RESEARCH, 2006, 66 (08)
  • [35] AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children with a clinical diagnosis of androgen insensitivity
    Akcay, T.
    Fernandez-Cancio, M.
    Turan, S.
    Gueran, T.
    Audi, L.
    Bereket, A.
    ANDROLOGY, 2014, 2 (04) : 572 - 578
  • [36] Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer
    Li, Xia
    Huang, Yan
    Fu, Xuping
    Chen, Chengwen
    Zhang, Deqiang
    Yan, Lili
    Xie, Yi
    Mao, Yanjun
    Li, Yao
    MUTAGENESIS, 2011, 26 (03) : 371 - 383
  • [37] POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2 (5α-Reductase Type II) GENES IN PROSTATE CANCER
    Izmirli, M.
    Arikan, B.
    Bayazit, Y.
    Alptekin, D.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2011, 14 (01) : 31 - 35
  • [38] The association of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
    Onen, Ilke Hacer
    Ekmekci, Abdullah
    Eroglu, Muzaffer
    Polat, Fazli
    Biri, Hasan
    DNA AND CELL BIOLOGY, 2007, 26 (02) : 100 - 107
  • [39] Expression of CSF1, AR, and SRD5A2 during Postnatal Development of the Boar Reproductive Tract
    Katleba, Kimberley
    Legacki, Erin
    Berger, Trish
    ANIMALS, 2022, 12 (17):
  • [40] Association of prostate cancer and benign prostate hyperplasia with polymorphisms in VDR gene, CYP17 gene and SRD5A2 gene among Lebanese men.
    Kuddus, Ruhul H.
    El Ezzi, Asmahan A.
    El-saidi, Mohammed A.
    CANCER RESEARCH, 2013, 73 (08)